BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2023 8:11:23 AM | Browse: 299 | Download: 665
 |
Received |
|
2023-05-29 08:40 |
|
Peer-Review Started |
|
2023-05-29 08:42 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-06-20 03:47 |
|
Revised |
|
2023-07-22 14:04 |
|
Second Decision |
|
2023-08-14 02:57 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-08-15 09:25 |
|
Articles in Press |
|
2023-08-15 09:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-08-10 00:05 |
|
Typeset the Manuscript |
|
2023-08-21 08:01 |
|
Publish the Manuscript Online |
|
2023-09-01 08:11 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Joyce Wing Yan Mak, Alvin Wing Hin Law, Kimmy Wan Tung Law, Rita Ho, Carmen Ka Man Cheung and Man Fai Law |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Man Fai Law, MRCP, Doctor, Doctor, Department of Medicine and Therapeutics, Prince of Wales Hospital, 30-32 Ngai Shing Street, Shatin, Hong Kong 852, China. mflaw99@yahoo.com.hk |
| Key Words |
Hepatitis B; Hematologic neoplasms; Chimeric antigen receptor-T cell therapy; Monoclonal antibodies; Bruton’s tyrosine kinase inhibitors; Antiviral agents |
| Core Tip |
Patients with chronic or past resolved hepatitis B virus (HBV) infection are at risk of reactivation of the virus when they receive chemotherapy or immunosuppressive therapy. Therefore, before treatment, patients should be screened for HBV markers, specifically hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen. Prophylactic antiviral therapy is important for HBsAg-positive patients, and is a reasonable option for patients with resolved HBV infection who are scheduled to receive high-risk therapy such as anti-CD20 monoclonal antibodies, anti-CD79 monoclonal antibodies, bispecific antibodies, chimeric antigen receptor-T cell therapy, or hematopoietic stem cell transplantation. For other patients with resolved HBV infection, pre-emptive antiviral therapy guided by serial monitoring of HBV DNA is a reasonable option. |
| Publish Date |
2023-09-01 08:11 |
| Citation |
Mak JWY, Law AWH, Law KWT, Ho R, Cheung CKM, Law MF. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World J Gastroenterol 2023; 29(33): 4942-4961 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i33/4942.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i33.4942 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
